Pharma Tech

Delix Therapeutics raises $100m for zalsupindole development

Nov 10, 2026, 10:22 AM

Read Full Article → Delix Therapeutics raises $100m for zalsupindole development

Translate article text

Choose a language and wait for the translated text.

Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.